Table 2.
Cases suspicious for irAEs following COVID-19 mRNA vaccine administration.
| Age/Sexa | Cancer | ICIb | Vaccine manufacturer | Symptoms onset after vaccination | Symptoms or diagnosis | Comments |
|---|---|---|---|---|---|---|
| 79/F | Lung cancer | Pembrolizumab | Pfizer-BioNTech | 7 days | Respiratory distress | History of pembrolizumab associated pneumonitis |
| 37/M | Thymus cancer | Pembrolizumab | Pfizer-BioNTech | 1 day | Acute hemolytic anemia | Labs consistent with haemolytic anaemia |
| 48/M | Kidney cancer | Ipilimumab/nivolumab | Moderna | Same day | Shock requiring pressor support | Home medication includes hydrocortisone 10 mg/5 mg; history of adrenal insufficiency |
| 70/M | Prostate cancer | Pembrolizumab | Pfizer-BioNTech | 1 day | Myositis | Labs/Imaging work-up consistent with inflammatory myositis; last pembrolizumab was 2 months ago |
| 77/F | Lung cancer | Pembrolizumab | Pfizer-BioNTech | 4 days | Cardiogenic shock | Coronary angiography showed no significant narrowing or blockage; labs showed elevated troponins |
| 68/M | Sarcoma | Pembrolizumab | Moderna | 5 days | Pancreatitis/rash | No prior history of pancreatitis |
a
M: male; F: female.
b
ICI: immune checkpoint inhibitor.